Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·How do breast cancer risk genes relate to treatment when tumors vary?
Review or Meta-AnalysisA 2021 survey covers BRCA1’s roles in cell division and DNA-damage response, and why tumor diversity complicates breast cancer treatment research.
-
Evidence date ·What the mulberry review found about movement, memory and stroke
Review or Meta-AnalysisA 47-study review reported better Parkinson-like movement with fruit extracts and greater drug-induced immobility with a leaf extract in separate animal experiments.
-
Evidence date ·Looking at T-cell proteins to understand dysfunction inside tumors
Review or Meta-AnalysisA 2021 review explores how mass spectrometry could measure many proteins at once to study T-cell dysfunction inside tumors.
-
Evidence date ·Why some thyroid tumors stop absorbing radioactive iodine—and what might restore it
Review or Meta-AnalysisA review describes restored iodine uptake in small patient groups and why tumor genetics matter. The findings do not establish lasting benefit for everyone.
-
Evidence date ·What can a falling brain resistance reading during sleep reveal?
Peer-Reviewed PaperIn healthy adults, brain impedance fell across the night and during key sleep stages with stimulation. The reading suggests fluid-related change, not proven waste removal.
-
Evidence date ·What changed in old mouse kidneys after eight months of treatment?
Peer-Reviewed PaperAfter eight months of dasatinib and quercetin, aged mice had less kidney scarring and fewer tubular fat droplets. The study did not measure kidney function.
-
Evidence date ·Why finding breast cancer targets may not be enough for CAR-T therapy
Review or Meta-AnalysisA 2026 review examines HER2, EGFR and MUC1 as breast cancer targets, plus tumor diversity and safety risks. Its abstract does not establish patient benefit.
-
Evidence date ·Two roles for sugar-based particles in cancer immunotherapy
Review or Meta-AnalysisA review contrasts β-glucan, which can engage immune-cell receptors, with adaptable dextran carriers. Mouse studies and clinical uses answer different questions.
-
Evidence date ·Why might clearing aging cells call for a different immune attack than cancer?
Review or Meta-AnalysisA 2026 review surveys engineered T-cell studies in liver and heart models, then examines target overlap and safety barriers to clearing aging cells in people.
-
Evidence date ·A damaged disc may need its tissue-building cells back
Review or Meta-AnalysisA review proposes clearing aging disc cells, restoring healthy gene activity, then adding replacement cells. Human disc regeneration remains unproven.